Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...

Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it raised its sales growth ...

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, Blueprint acquisition, strong ...

Digitization has allowed Sanofi to optimize manufacturing and automate document preparation. And now, the firm predicts that ...

The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...

Additionally, Sanofi's spread between returns on invested capital and cost of capital has historically been narrow, and once Dupixent comes off patent, this spread could face significant compression.

Sanofi expects Dupixent to achieve more than €13 billion in sales in 2024. For Regeneron, Dupixent generated collaboration revenues of $2.06 billion in the first half, up 18% year over year.

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...

--Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has approved Dupixent ® as an add-on maintenance treatment for adolescent patients aged 12 ...